Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichèle Cavo, Antonio Palumbo, Lucia Pantani et al.|Blood|2012Cited by 310
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.Michèle Cavo, Michele Baccarani, Nicoletta Testoni et al.|Blood|2008Cited by 10
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.Federica Cavallo, Antonio Palumbo, Francesco Di Raimondo et al.|Blood|2010Cited by 9
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS.Federica Cavallo, Antonio Palumbo, Tommaso Caravita et al.|Unknown|2011Cited by 3
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDMAnnamaria Brioli, Michèle Cavo, Antonio Lazzaro et al.|Blood|2014Cited by 3